Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer
January 08 2020 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated
biologics contract development and manufacturing organization
(CDMO) working to improve patient lives by providing high quality
development and manufacturing services to biotechnology and
pharmaceutical companies, today announced the appointment of
Timothy Compton as chief commercial officer. Mr. Compton is
an accomplished professional who possesses extensive experience in
commercial operations, including sales team management, business
development, marketing and corporate development. In his new
role, he will be responsible for driving the continued growth of
Avid’s CDMO business, including the ongoing expansion of the
company’s commercial and clinical client base. Mr. Compton is
replacing Tracy Kinjerski, who has left the company to pursue other
opportunities.
Mr. Compton most recently served as senior
director of sales and business development for Cambrex Corporation,
a leading small molecule CDMO, where he managed the company’s
Western North America and Asia Pacific CDMO sales and business
development team. Following Cambrex’s 2019 acquisition of
Avista Pharma Solutions, he played a key role in transitioning
Avista’s commercial operations practices to Cambrex. Prior to
its sale to Cambrex, Mr. Compton was vice president of sales for
Avista, overseeing sales, business development and business
operations across all the company’s service offerings, driving
significant year-over-year revenue growth. Mr. Compton held
multiple senior level positions with AAIPharma Services
Corporation, a CDMO now named Alcami, including executive director
of alliance management and executive director of business
development. His career has also included tenures with a
range of life science companies including Baypoint Biosystems, N.V.
Organon, Kadmus Pharmaceuticals and Atairgin Technologies.
“We are excited to have Tim join the Avid team
and contribute his broad CDMO industry experience to the continued
growth and expansion of our business. His track record of
driving impressive sales and revenue growth in this space positions
him ideally to serve as Avid’s chief commercial officer,”
said Rick Hancock, interim president and chief executive
officer of Avid. “On behalf of the company, I’d also like to
express my gratitude to Tracy Kinjerski for the important
contributions that she made during her time with Avid. We
wish her well in all of her future endeavors.”
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical products
derived from mammalian cell culture. The company provides a
comprehensive range of process development, high quality CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 25 years of
experience producing monoclonal antibodies and recombinant proteins
in batch, fed-batch and perfusion modes, Avid's services include
CGMP clinical and commercial product manufacturing, purification,
bulk packaging, stability testing and regulatory strategy,
submission and support. The company also provides a variety of
process development activities, including cell line development and
optimization, cell culture and feed optimization, analytical
methods development and product
characterization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024